PhaseBio Pharmaceuticals Gross Profit

PhaseBio Pharmaceuticals's gross profit stands at $820K as of June 2022. That compares with $11M in the prior-year period — down 92.3% year over year. That is below the Healthcare sector average of $63B. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

PhaseBio Pharmaceuticals reported $820K in gross profit versus $11M a year earlier — a 92.3% year-over-year decrease. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

PhaseBio Pharmaceuticals sits lower the Healthcare benchmark ($63B) with a gross profit of $820K. That is roughly 100.0% below the sector mean. Peer context matters because what looks expensive or cheap in absolute terms can be normal for the sector.

That compares with $11M in the prior-year period — down 92.3% year over year. Sustained growth in gross profit can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.

The history chart shows how PhaseBio Pharmaceuticals's gross profit evolved across reporting periods, while the comparison chart places PHAS next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.